SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

SINOVAC BIOTECH LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026

$6.47+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: 850.08%

Debt

Borrowings on the balance sheet, Dec 31, 2025

Sinovac Biotech reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Sinovac Biotech's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Sinovac Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SVA.

Revenue growth6.8% · median 13.2%

Gross margin67.9% · median 56.5%

Operating margin-127.0% · median 7.4%

Company	Revenue	Growth
ARQT	$463.98M	+76.1%
LQDA	$450.91M	+2233.6%
ZLAB	$449.61M	+5.1%
SVA	$386.01M	+6.8%
HCM	$204.89M	-4.3%
KMDA	$191.85M	+13.2%

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,602
Auditor: Zhonghua Certified Public Accountants LLP
SEC CIK: 1084201

Advertisement
300 × 250